email article Sacubitril/valsartan (Entresto) became the first drug to get a broad heart failure indication that reaches into the normal ejection fraction range for prevention of cardiovascular death and hospitalization, Novartis announced. FDA granted the drug an expanded indication "to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal." An advisory committee weighing approval in December voted unanimously in favor of expanding the angiotensin receptor–neprilysin inhibitor's indication beyond that in heart failure with reduced ejection fraction (HFrEF) based on the PARAGON-HF trial.